Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements.

Autor: Cullot G; Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Department of Biology, ETH Zurich, Zurich, Switzerland., Amintas S; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Department of Tumor Biology and Tumor Library, CHU Bordeaux, Bordeaux, France., Karembé L; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France., Prouzet-Mauléon V; Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; CRISP'edit, TBMCore, CNRS UAR3427, INSERM US005, University of Bordeaux, Bordeaux, France., Rébillard J; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France., Boureau L; Laboratory of Hematology, CHU Bordeaux, Bordeaux, France., Cappellen D; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Department of Tumor Biology and Tumor Library, CHU Bordeaux, Bordeaux, France., Bedel A; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Department of Biochemistry and Molecular Biology, CHU Bordeaux, Bordeaux, France., Moreau-Gaudry F; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Department of Biochemistry and Molecular Biology, CHU Bordeaux, Bordeaux, France., Dulucq S; Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Laboratory of Hematology, CHU Bordeaux, Bordeaux, France.; Fi-LMC Group, Léon Bérard Center, Lyon, France., Dabernat S; Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; Department of Biochemistry and Molecular Biology, CHU Bordeaux, Bordeaux, France., Turcq B; Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France.; CRISP'edit, TBMCore, CNRS UAR3427, INSERM US005, University of Bordeaux, Bordeaux, France.; Fi-LMC Group, Léon Bérard Center, Lyon, France.
Jazyk: angličtina
Zdroj: The CRISPR journal [CRISPR J] 2023 Apr; Vol. 6 (2), pp. 140-151. Date of Electronic Publication: 2023 Mar 13.
DOI: 10.1089/crispr.2022.0070
Abstrakt: Advances in molecular medicine have placed nucleic acid detection methods at the center of an increasing number of clinical applications. Polymerase chain reaction (PCR)-based diagnostics have been widely adopted for their versatility, specificity, and sensitivity. However, recently reported clustered regularly interspaced short palindromic repeats-based methods have demonstrated equivalent to superior performance, with increased portability and reduced processing time and cost. In this study, we applied Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) technology to the detection of oncogenic rearrangements. We implemented SHERLOCK for the detection of BCR::ABL1 mRNA, a hallmark of chronic myeloid leukemia (CML), and EGFR DNA oncogenic alleles, frequently detected in glioblastoma and non-small cell lung cancer (NSCLC). SHERLOCK enabled rapid, sensitive, and variant-specific detection of BCR::ABL1 and EGFR alterations. Compared with the gold-standard PCR-based methods currently used in clinic, SHERLOCK achieved equivalent to greater sensitivity, suggesting it could be a new tool in CML and NSCLC, to detect low level of molecular residual disease.
Databáze: MEDLINE
Externí odkaz: